607 related articles for article (PubMed ID: 11048517)
1. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
2. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice].
Dobiásová M
Vnitr Lek; 2006 Jan; 52(1):64-71. PubMed ID: 16526201
[TBL] [Abstract][Full Text] [Related]
3. [Lipanor treatment of atherogenic hyperlipoproteinemia].
Susekov AV; Tvorogova MG; Arabidze GG; Kukharchuk VV
Ter Arkh; 1998; 70(9):57-61. PubMed ID: 9821228
[TBL] [Abstract][Full Text] [Related]
4. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
Cubrilo-Turek M; Sertić J; Duraković Z
Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
[TBL] [Abstract][Full Text] [Related]
6. [Atherogenic index of plasma is associated with carotid intima-media thickness in patients with type 2 diabetes mellitus].
Hu YM; Tian HM; Liu R; Chen X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):696-8, 707. PubMed ID: 15460423
[TBL] [Abstract][Full Text] [Related]
7. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Kovács I; Tarján J; Császár A
Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.
Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J
Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220
[TBL] [Abstract][Full Text] [Related]
9. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
10. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Mikhailidis DP; Ganotakis ES; Spyropoulos KA; Jagroop IA; Byrne DJ; Winder AF
Int Angiol; 1998 Dec; 17(4):225-33. PubMed ID: 10204653
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma.
Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC
J Cardiovasc Pharmacol; 2006 Apr; 47(4):542-8. PubMed ID: 16680067
[TBL] [Abstract][Full Text] [Related]
12. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
13. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
Bersot TP; Pépin GM; Mahley RW
Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
[TBL] [Abstract][Full Text] [Related]
14. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
15. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein profile and prevalence of cardiovascular risk factors in urban Moroccan women.
El ayachi M; Mziwira M; Vincent S; Defoort C; Portugal H; Lairon D; Belahsen R
Eur J Clin Nutr; 2005 Dec; 59(12):1379-86. PubMed ID: 16118656
[TBL] [Abstract][Full Text] [Related]
17. Lipid and lipoprotein profile in physiological pregnancy.
Lippi G; Albiero A; Montagnana M; Salvagno GL; Scevarolli S; Franchi M; Guidi GC
Clin Lab; 2007; 53(3-4):173-7. PubMed ID: 17447654
[TBL] [Abstract][Full Text] [Related]
18. Relation of cholesterol esterification rate to the plasma distribution of high-density lipoprotein subclasses in normal and hypertensive women.
Dobiásová M; Stríbrná J; Frohlich JJ
Clin Invest Med; 1995 Dec; 18(6):449-54. PubMed ID: 8714788
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Wolf HR
Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
[TBL] [Abstract][Full Text] [Related]
20. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
Ceska R; Kvasnicka T; Haas T; Soska V; Vaverková H
Vnitr Lek; 2000 Mar; 46(3):157-60. PubMed ID: 11048518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
